This is surprising because pRB pathway components such as cyclin D1 are commonly amplified, and pRB itself is sometimes lost in human breast cancers and these are direct targets of CKI regulation [20], [21], [22], [23], [24]. This evidence concerns the gene RB1 and breast carcinoma.